NEO NeoGenomics Inc
Company Analysis
Latest News
🟢 NeoGenomics is trading 8.88% up in pre-market Rebound amid volatile recent trading
NeoGenomics is trading 8.88% up at $19.50, with the move appearing most consistent with a rebound in a volatile recent trading pattern. - It closed at $17.91...
🔴 NeoGenomics is trading 4.46% down today with no clear company-specific catalyst
NeoGenomics is trading 4.46% down at $17.25, with no new company announcement, earnings report, analyst action, or filing found to directly explain the...
🟢 NeoGenomics is trading 5.4% up in after-hours trading after Medicare expanded RaDaR ST coverage
NeoGenomics is trading 5.4% up now at $19.64 in after-hours trading after Medicare expanded coverage for RaDaR ST to monitor immunotherapy response in patients...
NeoGenomics Lands a Third Medicare Win for Its Blood-Based Cancer Test — But Can It Keep Pace in a Crowded Race?
Shares of NeoGenomics surged 10.2% to $19.14 after the company announced that Medicare will now pay for its blood-based cancer-monitoring test to track how...
🟢 NeoGenomics is trading 10.22% up today after CMS expanded Medicare coverage for RaDaR ST
NeoGenomics is trading 10.22% up now at $19.14 after CMS expanded Medicare coverage for its RaDaR ST molecular residual disease assay on August 26, 2026. -...
🟢 NeoGenomics is trading 4.3% up today after CMS expanded Medicare coverage for RaDaR ST
NeoGenomics is trading 4.3% up at $18.12 after CMS expanded Medicare coverage for its RaDaR ST molecular residual disease assay. - The August 26, 2026,...
🔴 NeoGenomics is trading 7% down in pre-market after no clear company-specific catalyst was identified
NeoGenomics is trading 7.07% down at $15.25 after no clear company-specific catalyst was identified for August 25, 2026. - Recent coverage highlights strong...
🔴 NeoGenomics is trading 5.77% down in pre-market after no clear company-specific catalyst was identified
NeoGenomics is trading 5.77% down now at $16.00 after no clear company-specific catalyst was identified for August 24, 2026. - Recent company updates include...
🟢 NeoGenomics rises 4.2% — Healthcare Stocks Surge on Strong Earnings Outlook and Investor Rotation
With Healthcare (XLV) up 3.2%, this looks like a sector-led move rather than a company-specific surprise. The healthcare sector experienced a significant...
🟢 NeoGenomics is trading 4.56% up today amid positive healthcare-sector momentum
NeoGenomics is trading 4.56% up now at $16.22, amid positive healthcare-sector momentum; no new company-specific announcement was identified for August 7,...
🟢 NeoGenomics is trading 4.09% up today amid a broader market rally
NeoGenomics is trading at $15.91 (+4.09%) during the live session, moving higher despite a lack of company-specific announcements or earnings catalysts. • The...
🟢 NeoGenomics is trading 5.3% up today following strong Q2 earnings and raised guidance
NeoGenomics is trading at $16.07 (5.3% up) as investors continue to react to its stronger-than-expected second quarter 2026 earnings and raised full-year...
🟢 NeoGenomics is trading 10% up today after strong Q2 earnings and upgraded guidance
NeoGenomics is trading at $14.75 (10% up) following a strong second-quarter earnings report and upgraded full-year guidance. • The company reported 11%...
NeoGenomics Beats Earnings and Raises Guidance, But Can a Cancer Diagnostics Firm Trading Near Its 52-Week High Keep the Momentum Going?
Shares of NeoGenomics surged 11.1% to $14.89 in pre-market trading on July 29, after the oncology diagnostics company posted second-quarter results that...
🟢 NeoGenomics is trading 11.1% up today on Q2 earnings beat and raised FY26 guidance
NeoGenomics is trading 11.1% up at $14.89 in pre-market following a strong second-quarter earnings report that beat revenue and EPS estimates. • The company...
🟢 NeoGenomics is trading 6.5% up today after Q2 earnings beat and raised guidance
NeoGenomics is trading at $14.27 (+6.48%) after reporting a stronger-than-expected second quarter and lifting its full-year guidance. • The company posted...
🟢 NeoGenomics is trading 6% up today after Q2 earnings beat and raised full-year guidance
NeoGenomics is trading 6% up at $14.20 in after-hours trading after reporting stronger-than-expected second quarter 2026 results and raising its full-year...
NeoGenomics beats second quarter 2026 estimates on 11% revenue growth and raises full-year guidance.
NeoGenomics reported second quarter revenue of $202 million, an 11% year-over-year increase, and GAAP EPS of $0.02, compared to a loss of $0.35 in the prior...
🔴 NeoGenomics is trading 5.5% down today as investors reposition ahead of Q2 earnings
NeoGenomics is trading 5.5% down at $13.13 as investors reposition ahead of its Q2 2026 earnings report scheduled for July 28, 2026. • The stock has shown...
NeoGenomics Inc Q2 2026 Earnings Preview: What Analysts Expect on July 28, 2026
NeoGenomics is expected to report Q2 2026 revenue of approximately $196.99 million and a consensus loss of $0.06 per share, with the current stock price of...